Current filters:


Popular Filters

1930 to 1954 of 2557 results

Small-molecule cancer drug revenues will reach $32.7 billion in 2016, says Visiongain


The small-molecule targeted cancer therapy revenues will reach a value of $32.7 billion worldwide in…

BiotechnologyGleevecGlivecGlobalMarkets & MarketingNovartisOncologyPharmaceutical

Tufts CSDD says drug developers need to identify and address root causes of R&D inefficiency


While patent expirations on many top selling medicines is spurring the research-based drug industry to…

BiotechnologyNorth AmericaPharmaceuticalRegulationResearch

2012 again a bumper year for Pharma M&A, but values well down


The year 2012 was again a bumper year for merger and acquisition activity in the global pharmaceutical,…

BiotechBiotechnologyGenericsMergers & AcquisitionsPharmaceutical

MacroGenics in deal potentially worth $1 billion with Gilead for DART products


Privately held US biotech firm MacroGenics has entered into a license agreement with Gilead Sciences…

BiotechnologyGilead SciencesLicensingMacroGenicsResearch

Amgen in $180 mill deal with BIND; Priaxon accord with GlaxoSmithKline


BIND Biosciences, a US clinical stage investor backed company, and Amgen (Nasdaq: AMNG), the world's…

AmgenBIND BiosciencesBiotechnologyGlaxoSmithKlineLicensingOncologyPharmaceuticalPriaxon

Shire to acquire Lotus Tissue Repair for undisclosed price


Ireland-headquartered drugmaker Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire…

BiotechnologyLotus Tissue RepairMergers & AcquisitionsPharmaceuticalRare diseasesShire

Sirtex shines as biotech gears up for big year, says AusBiotech


As the year commences, Australia's Sirtex Medical is being hailed a stand-out performer for 2012 and…

Asia-PacificBiotechnologyFinancialMesoblastPhosphagenicsSirtex MedicalStarpharma

BioAlliance says partner Vestiq debuts Oravig in USA


French biotech firm BioAlliance Pharma (Euronext Paris - BIO) has announces the launch of Oravig (miconazole…

BioAlliance PharmaBiotechnologyLoramycMarkets & MarketingNorth AmericaOncologyOravigPharmaceuticalVestiq Pharmaceuticals

Lonza to invest in new antibody drug conjugate manufacturing capacity to meet growing demand


Swiss pharmaceutical ingredients and specialty chemicals firm Lonza (SIX: LONN) plans to invest 14 million…


FDA approves SOBI's Kineret for the treatment of NOMID


Biotech firm Swedish Orphan Biovitrum (STO: SOBI) today announced that the US Food and Drug Administration…

AmgenBiotechnologyInflammatory diseasesKineretNorth AmericaRegulationSobiSwedish Orphan Biovitrum

arGEN-X expands antibody deal with Shire; initiates ARGX-110 trial in cancer


Netherlands and Belgium-based preclinical stage biotech firm arGEN-X, specialized in the discovery and…

arGEN-XARGX-110BiotechnologyLicensingOncologyRare diseasesResearchShire

Gilead Sciences updates on hepatitis C development programs


US biotech firm Gilead Sciences (Nasdaq: GILD) presented several updates regarding its late-stage pipeline…

Anti-viralsBiotechnologyGilead SciencesGS-5885Researchsofosbuvir

Big pharma will increasingly tap M&A to close $100 billion growth gap


Big pharma companies are facing a widening "growth gap" that will increase pressure to drive growth through…

BiotechnologyFinancialMergers & AcquisitionsPharmaceutical

Ethris enters SNIM modified RNA alliance with Shire


German biotech firm Ethris GmbH has initiated a research based alliance focused on the development and…

BiotechnologyEthris GmbHGeneticsLicensingPharmaceuticalResearchShire

Pharmaceutical M&A deals in 2012


Details for the 131 M&A announcements in 2012 recorded by The Pharma Letter are provided in the full…

BiotechGenericsMergers & AcquisitionsPharmaceutical

Biogen Idec files for US approval of hemophilia B treatment


US biotech firm Biogen Idec (Nasdaq: BIIB) on Friday announced it has submitted a Biologics License Application…

Biogen IdecBiotechnologyNorth AmericaRegulationrFIXFcrFVIIIFcSwedish Orphan Biovitrum

Eight US FDA approvals in December boost 2012 to banner year for new drugs


The US Food and Drug Administration approved eight new drugs in December pushing the year's total to…

BiotechnologyFinancialNorth AmericaPharmaceuticalRegulation

Biogen Idec to drop ALS drug after failure in Ph III trial


Shares of US biotech firm Biogen Idec (Nasdaq: BIIB) fell as much as 8% to $138.05 in pre-market trading…

Biogen IdecBiotechnologydexpramipexoleNeurologicalResearch

1930 to 1954 of 2557 results

Back to top